(Adnkronos) - “Lo studio clinico di Fase III E1910 dimostra che è significativamente prolungata la sopravvivenza nei pazienti che hanno ricevuto l'anticorpo bispecifico blinatumomab rispetto a quello che in inglese viene chiamato standard of care”. Lo spiega Robin Foà, professore emerito di Ematologia presso l’università Sapienza di Roma, a margine dell’evento con il quale Amgen ha illustrato i risultati dello studio clinico di Fase III E1910 che dimostrano come l'introduzione dell’anticorpo monoclonale bispecifico blinatumomab nella prima linea di trattamento aumenti significativamente la sopravvivenza globale dei pazienti affetti da leucemia linfoblastica acuta (Lla) da linfociti B Ph- di nuova diagnosi.
Category
🗞
NewsTranscript
00:00The study that just came out on New England Journal of Medicine is an important study
00:10because it demonstrates, in a randomized study, with a group of comparison, that the addition
00:16of the monoclonal antibody B-specific, Blinatum, which is a form of immunotherapy, because it
00:23recognizes the leukemic cell but activates the lymphocytes of the patient, is also active
00:28in patients with acute lymphoblastic leukemia, negative Philadelphia of line B, which are
00:35negative even for the minimal disease.
00:37This is a very important point, we have already demonstrated it, hypothesized it, also
00:43the Italian study in Gmema, but this is the first randomized study that demonstrates it
00:48in an unequivocal way, so it is an extremely important step forward for the treatment of
00:53these patients.
00:54First of all, the survival of randomized patients who received the antibody is significantly
01:00extended compared to what is called standard of care in English, the difference in survival
01:06is significantly higher, so it can change the approach, so much so, I add, that the
01:12FDA, the American regulatory body, in June of this year approved the antibody for the
01:20category of patients, I add, we trust that also in Europe the FDA will approve as soon
01:30as possible, to emphasize the importance of the drug for the patients.